Oramed Pharmaceuticals (ORMP)
Market Price (11/1/2026): $4.12 | Market Cap: $171.4 MilSector: Health Care | Industry: Biotechnology
Oramed Pharmaceuticals (ORMP)
Market Price (11/1/2026): $4.12Market Cap: $171.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 110%, Dividend Yield is 6.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 106% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Diabetes Management, and Biopharmaceutical R&D. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.4 | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null Key risksORMP key risks include [1] the Phase 3 failure of its lead oral insulin candidate, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 110%, Dividend Yield is 6.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 106% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Diabetes Management, and Biopharmaceutical R&D. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.4 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null |
| Key risksORMP key risks include [1] the Phase 3 failure of its lead oral insulin candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Oramed Pharmaceuticals (ORMP) stock has remained largely at the same level since 7/31/2026 because of the following key factors:
1. Strong Q2 fiscal year 2026 EPS beat, but zero revenue and focus on strategic investments muted impact. Oramed Pharmaceuticals reported its Q2 fiscal year 2026 earnings on August 10, 2026, with an Earnings Per Share (EPS) of $1.84, significantly exceeding the consensus estimate of $0.43 by 327.91%. However, the company reported $0.00 in both actual and estimated revenues. This indicates that the substantial EPS was primarily driven by non-operating income, consistent with Oramed's strategic shift towards becoming an investment company rather than solely relying on drug development revenue. The lack of revenue from its core pharmaceutical business likely dampened investor enthusiasm, preventing a significant stock surge despite the impressive EPS figure.
2. Lack of new major clinical trial catalysts for the core drug pipeline. During the specified period, there were no announcements of significant new clinical trial readouts or advancements for Oramed's core drug pipeline, including its oral insulin candidate, ORMD-0801. The company's previous Phase 3 oral insulin trial (ORA-D-013-1) failed to meet its primary and secondary endpoints in early 2023, leading to its termination and a parallel trial. While Oramed continues to advance ORMD-0801 through its investment in Lifeward, the absence of fresh, positive clinical data for its primary pharmaceutical assets meant a lack of immediate catalysts to drive substantial stock appreciation.
Show more
Oramed Pharmaceuticals (ORMP) stock has remained largely at the same level since 7/31/2026 because of the following key factors:
1. Strong Q2 fiscal year 2026 EPS beat, but zero revenue and focus on strategic investments muted impact. Oramed Pharmaceuticals reported its Q2 fiscal year 2026 earnings on August 10, 2026, with an Earnings Per Share (EPS) of $1.84, significantly exceeding the consensus estimate of $0.43 by 327.91%. However, the company reported $0.00 in both actual and estimated revenues. This indicates that the substantial EPS was primarily driven by non-operating income, consistent with Oramed's strategic shift towards becoming an investment company rather than solely relying on drug development revenue. The lack of revenue from its core pharmaceutical business likely dampened investor enthusiasm, preventing a significant stock surge despite the impressive EPS figure.
2. Lack of new major clinical trial catalysts for the core drug pipeline. During the specified period, there were no announcements of significant new clinical trial readouts or advancements for Oramed's core drug pipeline, including its oral insulin candidate, ORMD-0801. The company's previous Phase 3 oral insulin trial (ORA-D-013-1) failed to meet its primary and secondary endpoints in early 2023, leading to its termination and a parallel trial. While Oramed continues to advance ORMD-0801 through its investment in Lifeward, the absence of fresh, positive clinical data for its primary pharmaceutical assets meant a lack of immediate catalysts to drive substantial stock appreciation.
3. Balancing act of strategic investment returns and inherent uncertainties. Oramed has successfully generated substantial returns from its strategic investments, notably recouping $118 million from a loan to Scilex, with an additional $43 million expected by October 2026. The value of its stake in Alpha Tau Medical also nearly tripled from an initial $38.2 million. While these financial successes provide stability and profitability, they also represent a shift in the company's narrative from a high-growth biotech to one that balances drug development with an investment portfolio. This diversification, while beneficial for mitigating risk, may lead investors to view the stock as less prone to rapid, explosive growth tied to pharmaceutical breakthroughs, resulting in a more stable, sideways trading pattern as the market assesses the long-term impact and sustainability of these varied holdings.
4. Market anticipation of upcoming Q3 fiscal year 2026 earnings. As the period concluded on October 31, 2026, the market was in a "holding pattern" awaiting the estimated Q3 fiscal year 2026 earnings report, scheduled for November 12, 2026. This report, which would cover the company's performance up to September 30, 2026, was a significant upcoming event. Investors likely adopted a wait-and-see approach, refraining from making large directional bets until more definitive financial updates were released, contributing to the stock remaining largely at the same level.
5. Disconnect between analyst price targets and actual stock performance. Despite some analysts maintaining "Buy" or "Strong Buy" ratings for ORMP and projecting price targets ranging from $7.00 to $7.14 per share, the stock did not converge towards these elevated targets during the analysis period. For instance, on October 30, 2026, one analyst's target implied a 65.48% upside from the $4.23 closing price, and on September 15, 2026, the average target of $7.14 suggested a 52.89% upside from $4.67. This persistent gap between analyst expectations and actual trading range suggests that market participants, while acknowledging potential, exercised caution due to the company's transitional phase and its reliance on non-core business activities for profitability, preventing a sustained upward price movement.
Show less
Stock Movement Drivers
Fundamental Drivers
The 1.0% change in ORMP stock from 7/31/2026 to 10/31/2026 was primarily driven by a 0.0% change in the company's Net Income Margin (%).| (LTM values as of) | 7312026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.07 | 4.11 | 1.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| Net Income Margin (%) | ∞% | ∞% | 0.0% |
| P/E Multiple | 1.5 | 1.0 | -36.1% |
| Shares Outstanding (Mil) | 41 | 41 | -0.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ORMP | 1.0% | |
| Market (SPY) | 1.2% | 23.6% |
| Sector (XLV) | 13.7% | 18.2% |
Fundamental Drivers
The 5.9% change in ORMP stock from 4/30/2026 to 10/31/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Net Income Margin (%).| (LTM values as of) | 4302026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.88 | 4.11 | 5.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | |
| Net Income Margin (%) | 3202.5% | ∞% | 9.2233720368547763E17% |
| P/E Multiple | 2.5 | 1.0 | -61.1% |
| Shares Outstanding (Mil) | 41 | 41 | -0.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ORMP | 5.9% | |
| Market (SPY) | 5.4% | 17.3% |
| Sector (XLV) | 27.2% | 4.6% |
Fundamental Drivers
The 84.5% change in ORMP stock from 10/31/2025 to 10/31/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.23 | 4.11 | 84.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | |
| P/S Multiple | 46.5 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 42 | 41 | 1.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ORMP | 84.5% | |
| Market (SPY) | 11.7% | 28.3% |
| Sector (XLV) | 29.8% | 19.2% |
Fundamental Drivers
The 140.9% change in ORMP stock from 10/31/2023 to 10/31/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 10312023 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.71 | 4.11 | 140.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 0 | |
| P/S Multiple | 25.4 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 40 | 41 | -2.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2023 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ORMP | 140.9% | |
| Market (SPY) | 86.9% | 21.2% |
| Sector (XLV) | 55.5% | 16.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ORMP Return | 237% | -16% | -81% | 5% | 18% | 55% | 4% |
| Peers Return | 41% | 16% | 18% | 22% | 7% | -4% | 141% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| ORMP Win Rate | 83% | 42% | 50% | 42% | 50% | 60% | |
| Peers Win Rate | 56% | 48% | 42% | 46% | 40% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ORMP Max Drawdown | -56% | -74% | -87% | -42% | -23% | -24% | |
| Peers Max Drawdown | -30% | -44% | -49% | -47% | -46% | -35% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LLY, PFE, VKTX, RANI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/30/2026 (YTD)
How Low Can It Go
| Event | ORMP | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -14.2% | -18.8% |
| % Gain to Breakeven | 16.5% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -11.2% | -7.8% |
| % Gain to Breakeven | 12.7% | 8.5% |
| Time to Breakeven | 39 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -41.8% | -9.5% |
| % Gain to Breakeven | 71.9% | 10.5% |
| Time to Breakeven | 90 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.6% | -33.7% |
| % Gain to Breakeven | 90.8% | 50.9% |
| Time to Breakeven | 310 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -38.0% | -19.2% |
| % Gain to Breakeven | 61.3% | 23.8% |
| Time to Breakeven | 336 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -23.4% | -3.7% |
| % Gain to Breakeven | 30.5% | 3.9% |
| Time to Breakeven | 173 days | 6 days |
In The Past
Oramed Pharmaceuticals's stock fell -14.2% during the 2025 US Tariff Shock. Such a loss loss requires a 16.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ORMP | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -41.8% | -9.5% |
| % Gain to Breakeven | 71.9% | 10.5% |
| Time to Breakeven | 90 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.6% | -33.7% |
| % Gain to Breakeven | 90.8% | 50.9% |
| Time to Breakeven | 310 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -38.0% | -19.2% |
| % Gain to Breakeven | 61.3% | 23.8% |
| Time to Breakeven | 336 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -23.4% | -3.7% |
| % Gain to Breakeven | 30.5% | 3.9% |
| Time to Breakeven | 173 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -63.2% | -6.8% |
| % Gain to Breakeven | 171.8% | 7.3% |
| Time to Breakeven | 919 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -45.0% | -0.2% |
| % Gain to Breakeven | 81.7% | 0.2% |
| Time to Breakeven | 183 days | 1 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -21.4% | -15.4% |
| % Gain to Breakeven | 27.2% | 18.2% |
| Time to Breakeven | 902 days | 125 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -23.9% | -8.6% |
| % Gain to Breakeven | 31.4% | 9.5% |
| Time to Breakeven | 143 days | 47 days |
In The Past
Oramed Pharmaceuticals's stock fell -14.2% during the 2025 US Tariff Shock. Such a loss loss requires a 16.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company dedicated to the research and development of novel oral drug delivery systems. Headquartered in New York, the company's core mission revolves around creating orally ingestible capsules and pills for the efficient delivery of polypeptides, with a primary focus on improving treatments for chronic conditions such as diabetes.
The company's flagship product in development is ORMD-0801, an oral insulin capsule specifically designed for individuals with diabetes, which has successfully completed Phase II clinical trials. Expanding its pipeline for diabetes care, Oramed is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule for type 2 diabetes, which has completed Phase I studies. Beyond diabetes, the company is also working on an oral leptin capsule aimed at weight loss treatment.
Oramed Pharmaceuticals primarily targets the significant market of individuals with diabetes who could benefit from more convenient, non-injectable treatment options for insulin and GLP-1. Furthermore, with its oral leptin capsule in development, the company aims to serve the broader market of patients seeking innovative, orally administered solutions for weight management.
AI Analysis | Feedback
Here are a few analogies to describe Oramed Pharmaceuticals:
- It's like the "Eli Lilly or Novo Nordisk for oral diabetes medications," focused on turning typically injected drugs like insulin and GLP-1 into convenient pills.
AI Analysis | Feedback
- ORMD-0801: An orally ingestible insulin capsule developed for the treatment of individuals with diabetes.
- ORMD-0901: An oral glucagon-like peptide-1 (GLP-1) capsule designed for the treatment of type 2 diabetes.
- Oral leptin capsule: A developmental oral capsule intended as a weight loss treatment.
AI Analysis | Feedback
Based on the provided information, Oramed Pharmaceuticals Inc. (ORMP) is a pharmaceutical company primarily focused on research and development. Its proprietary products, including ORMD-0801 (oral insulin), ORMD-0901 (oral GLP-1), and an oral leptin capsule, are currently in various stages of clinical trials (Phase I and Phase II) and have not yet been commercialized or approved for sale.
Consequently, Oramed Pharmaceuticals does not currently have major customers, either other companies or individuals, as it is not actively selling its pipeline products on the market.
AI Analysis | Feedback
Major Suppliers:
- PolyPeptide Group AG (symbol: PPGN)
- Pharmaleads SA
- Ajinomoto Co., Inc. (symbol: 2802)
AI Analysis | Feedback
Nadav Kidron, Esq. Chief Executive Officer, President & Chairman
Mr. Kidron co-founded Oramed Pharmaceuticals in 2006. He is an entrepreneur with experience in senior executive roles across various industries. He also co-founded Oravax Medical, a joint venture with Oramed and Premas Biotech, where he serves as Chairman of the Board. Additionally, he co-founded Entera Bio, a joint venture formed by Oramed and DNA Biomedical Solutions.
Avraham Gabay Chief Financial Officer, Treasurer & Secretary
Mr. Gabay was re-appointed Chief Financial Officer of Oramed Pharmaceuticals in June 2024, having previously held the position from 2019 to 2021. Prior to his current role, he served as interim CFO at BiomX Inc. from 2023 to 2024 and as CFO at Oravax Inc., a 63% owned subsidiary of Oramed, from 2021 to 2023. From 2015 to 2019, he was VP Finance at Orcam Technologies Ltd. He also provided economic services in the advisory department of KPMG Israel and worked in the tax department of Gornitzky & Co.
Miriam Kidron, PhD Chief Scientific Officer & Director
Dr. Kidron co-founded Oramed Pharmaceuticals in 2006. She is a pharmacologist and biochemist, holding a PhD in biochemistry from the Hebrew University of Jerusalem. For close to 20 years, she served as a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, and was formerly a visiting professor at the Medical School at the University of Toronto.
Josh Hexter Chief Operating & Business Officer
Mr. Hexter serves as Chief Operating and Business Officer of Oramed Pharmaceuticals. He brings nearly two decades of leadership, business development, and operations expertise in the life science sector. Before his current position, he was Chief Business Officer of BrainsWay Ltd. and previously served as Chief Operating Officer of Oramed.
Michael Rabinowitz Chief Commercial Officer
Mr. Rabinowitz was appointed Chief Commercial Officer in August 2021. He has over 20 years of experience from Merck & Co., where he held various marketing, sales, business development, and financial leadership roles both in the U.S. and globally. At Merck, he successfully launched and marketed products in more than 30 countries, including billion-dollar oral agents for diabetes.
```AI Analysis | Feedback
Oramed Pharmaceuticals Inc. (ORMP) faces several key risks inherent to its business model as a clinical-stage pharmaceutical company focused on novel drug delivery systems.
- Clinical Trial Failure and Regulatory Approval: The most significant risk to Oramed Pharmaceuticals is the potential for further clinical trial failures and difficulties in obtaining regulatory approval for its drug candidates. The company's flagship product, ORMD-0801 (oral insulin), failed to meet its primary and secondary endpoints in a pivotal Phase 3 clinical trial for Type 2 diabetes in January 2023, leading to a substantial drop in the company's share price and prompting a strategic reassessment. While Oramed is now attempting to reinitiate a Phase 3 trial with an amended protocol, focusing on a specific subgroup of patients, the ultimate success and regulatory clearance for this or any other pipeline product remain highly uncertain. The entire valuation of a platform technology company like Oramed is heavily dependent on successful clinical translation and regulatory approval. Strict FDA regulations for clinical trial design and execution, particularly for novel delivery methods, increase time-to-market risk and the potential for delays.
- Intellectual Property (IP) Protection and Challenges: Oramed's business relies heavily on its proprietary Protein Oral Delivery (POD) technology. However, there is a significant risk that the company may face difficulties or delays in obtaining, maintaining, or enforcing strong patent protection for its product candidates and core technology. For instance, an Oramed patent application for an oral insulin composition was previously refused in India due to a lack of inventive step, although this decision was later remanded for a fresh hearing. This highlights the challenges and uncertainties involved in securing robust intellectual property rights globally, which are crucial for protecting its innovative delivery platform from competition.
- Financial Health and Funding: As a research and development-focused pharmaceutical company, Oramed Pharmaceuticals operates with significant operational challenges, as evidenced by its negative operating margin. Despite having a cash position that provides a runway for a few years, the company continuously burns cash to fund its research, development, and clinical trial activities. The inability to obtain additional funding when required, through licensing fees, partnerships, or equity offerings, poses a substantial risk. Future capital raises could be expensive and result in dilution for existing shareholders, particularly after the setback of the oral insulin Phase 3 trial, which has impacted market sentiment and stock price volatility. Furthermore, the company's investments in small-cap biotechs as part of its asset base also expose it to market and credit risks.
AI Analysis | Feedback
AI Analysis | Feedback
Oramed Pharmaceuticals Inc. develops pharmaceutical solutions for diabetes and orally ingestible capsules for polypeptides, with key products including an oral insulin capsule (ORMD-0801), an oral glucagon-like peptide-1 (GLP-1) capsule (ORMD-0901), and an oral leptin capsule for weight loss.
Addressable Markets for Oramed Pharmaceuticals' Main Products:
- ORMD-0801 (Oral Insulin Capsule): The global oral insulin market was valued at approximately USD 564 million in 2025 and is projected to reach about USD 989 million by 2033, growing at a Compound Annual Growth Rate (CAGR) of 5.6% during this period.
- ORMD-0901 (Oral Glucagon-Like Peptide-1 (GLP-1) Capsule): The global oral GLP-1 receptor agonist drug market was valued at USD 22.0 billion in 2025 and is projected to expand to an estimated USD 103.4 billion by 2034, with a CAGR of 18.5% from 2026 to 2034.
- Oral Leptin Capsule (for weight loss treatment): A specific addressable market size for oral leptin capsules was not explicitly identified. However, the broader global oral obesity therapies market, which includes various oral medications for weight management, was valued at USD 4.35 billion in 2025. This market is predicted to increase to approximately USD 9.34 billion by 2035, expanding at a CAGR of 7.94% from 2026 to 2035. North America held the largest revenue share of the oral obesity therapies market in 2025.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Oramed Pharmaceuticals (ORMP) over the next 2-3 years:
- Royalty payments from the commercialization of oral insulin (ORMD-0801) in China: Through the joint venture OraTech Pharmaceuticals Inc. with Hefei Tianhui Biotech Co., Ltd. (HTIT), a Marketing Authorization Application for oral insulin has been submitted in China, and commercialization preparations are underway. OraTech is anticipated to receive royalty payments from these sales.
- Advancement and commercialization of oral insulin (ORMD-0801) in the U.S. and other global markets: OraTech Pharmaceuticals, the joint venture, is focused on conducting Phase 3 trials and pursuing regulatory registrations for oral insulin globally, including a new Phase 3 trial in the U.S. A successful progression through clinical trials and eventual market approval would be a significant revenue driver.
- Revenue generation from the strategic transaction with Lifeward Ltd.: In January 2026, Oramed entered into binding agreements to transfer its proprietary Protein Oral Delivery (POD™) technology to Lifeward Ltd. Oramed is expected to obtain a 49.9% beneficial ownership interest in Lifeward and will manage an anticipated clinical trial related to the oral delivery platform, potentially leading to future revenue streams or gains from its ownership stake.
- Ongoing royalty streams from the Scilex partnership: Oramed receives continuous revenue from its partnership with Scilex, including royalty streams from the sales of multiple Scilex products such as ZTlido, ELYXYB, and GLOPERBA. These existing royalty agreements are expected to contribute to Oramed's revenue in the coming years.
AI Analysis | Feedback
Share Repurchases
- Oramed's Board of Directors authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock, initially announced on June 26, 2024, and extended until June 2026.
- In December 2025, the company repurchased 1,155,367 shares of its common stock from Hefei Tianhui Biotech Co., Ltd. for approximately $2.58 million, which were subsequently canceled and retired.
Share Issuance
- In November 2021, Oramed completed a registered direct offering, issuing 2,000,000 shares of its common stock at a purchase price of $25 per share, resulting in expected gross proceeds of $50 million.
- The number of shares outstanding for Oramed Pharmaceuticals Inc. increased by 3.29% in the last year.
Outbound Investments
- In January 2026, Oramed and Lifeward Ltd. announced a strategic transaction that involved the transfer of Oramed's proprietary Protein Oral Drug (POD™) delivery technology to Lifeward. Oramed is to obtain a 49.9% beneficial ownership interest in Lifeward, including warrants, and plans to invest $9 million in senior secured convertible notes, with an additional milestone-based $9 million investment in convertible notes.
- As of January 7, 2026, Oramed received an $18 million payment from Scilex Holdings Inc., bringing its total returns to $118 million on its original $99.5 million Scilex investment. Oramed continues to hold a $27 million note and a $12 million convertible note with Scilex, along with warrant positions and a nine-year royalty interest in Scilex products.
- Oramed received $28.5 million in aggregate payments from Scilex in December 2025 for the repurchase of warrants to purchase a total of 6,500,000 shares of Scilex common stock.
Capital Expenditures
- Oramed Pharmaceuticals' capital expenditures in the last 12 months totaled -$18,000.
- Capital expenditures in the most recent quarter were $0.000.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 10.9% | 56.8% | 98.5% | CAH 480% · MCK 390% · COR 186% |
| Health Care Services | 20 | 33.8% | 44.0% | 12.4% | HIMS 255% · RDNT 136% · DGX 89% |
| Managed Health Care | 8 | 34.4% | -1.2% | -3.6% | OSCR 76% · HQY 55% · ELV 4% |
| Health Care Facilities | 25 | 12.1% | 18.2% | -5.4% | THC 281% · NHC 236% · EHC 182% |
| Health Care Equipment | 50 | 0.7% | 10.2% | -17.8% | GKOS 420% · UFPT 360% · PLSE 148% |
| Pharmaceuticals | 61 | -15.0% | 9.2% | -34.9% | LQDA 1102% · KNSA 788% · LLY 482% |
| Health Care Supplies | 11 | 15.5% | 2.3% | -39.9% | LNTH 329% · HAE 74% · MMSI 28% |
| Life Sciences Tools & Services | 107 | -8.1% | -1.9% | -66.4% | NTRA 262% · AXGN 225% · MEDP 188% |
| Biotechnology ← | 363 | -25.0% | -26.2% | -81.1% | DNTH 1187% · ELVN 1129% · TRVI 1054% |
| Health Care Technology | 21 | -23.8% | -48.9% | -82.4% | VEEV -1% · DOCS -53% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Oramed Pharmaceuticals Earnings Notes | 12/16/2025 | |
| Can Oramed Pharmaceuticals Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 26.99 |
| Mkt Cap | 3.2 |
| Rev LTM | 5 |
| Op Inc LTM | -15 |
| FCF LTM | -7 |
| FCF 3Y Avg | -8 |
| CFO LTM | -5 |
| CFO 3Y Avg | -8 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 22.6% |
| Rev Chg 3Y Avg | 17.1% |
| Rev Chg Q | 20.6% |
| QoQ Delta Rev Chg LTM | 8.5% |
| Op Inc Chg LTM | 2.1% |
| Op Inc Chg 3Y Avg | 21.5% |
| Op Mgn LTM | 26.7% |
| Op Mgn 3Y Avg | 31.2% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | 21.0% |
| CFO/Rev 3Y Avg | 22.7% |
| FCF/Rev LTM | 13.5% |
| FCF/Rev 3Y Avg | 10.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Research and development activities related to its proprietary products and technologies | 2 | 0 | 1 | ||
| Single Segment | 3 | 1 | |||
| Total | 2 | 0 | 1 | 3 | 1 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Research and development activities related to its proprietary products and technologies | 231 | 155 | |
| Single Segment | 221 | ||
| Total | 231 | 155 | 221 |
Price Behavior
| Market Price | $4.11 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 05/01/2007 | |
| Distance from 52W High | -23.0% | |
| 50 Days | 200 Days | |
| DMA Price | $4.57 | $4.03 |
| DMA Trend | up | up |
| Distance from DMA | -10.0% | 2.0% |
| 3M | 1YR | |
| Volatility | 36.1% | 53.3% |
| Downside Capture | 93.86 | 113.63 |
| Upside Capture | 88.57 | 174.25 |
| Correlation (S&P 500) | 11.0% | 26.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.02 | 0.60 | 0.86 | 0.74 | 1.18 | 0.74 |
| Up Beta | 2.88 | -0.82 | 0.42 | -0.17 | 0.33 | 0.49 |
| Down Beta | 0.60 | 1.35 | 0.83 | 0.16 | 0.75 | 0.46 |
| Up Capture | 0% | -12% | 95% | 116% | 288% | 136% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 8 | 16 | 29 | 58 | 122 | 349 |
| Down Capture | 182% | 139% | 96% | 116% | 119% | 100% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 13 | 25 | 31 | 63 | 118 | 361 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ORMP | |
|---|---|---|---|---|
| ORMP | 86.5% | 53.3% | 1.34 | - |
| Sector ETF (XLV) | 30.2% | 16.4% | 1.41 | 19.2% |
| Equity (SPY) | 10.9% | 12.8% | 0.52 | 28.0% |
| Gold (GLD) | -2.0% | 28.6% | -0.08 | 9.7% |
| Commodities (DBC) | 48.2% | 20.6% | 1.79 | -8.5% |
| Real Estate (VNQ) | 10.2% | 13.7% | 0.45 | 11.8% |
| Bitcoin (BTCUSD) | -30.0% | 43.5% | -0.70 | 22.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ORMP | |
|---|---|---|---|---|
| ORMP | -27.9% | 78.5% | 0.02 | - |
| Sector ETF (XLV) | 8.7% | 15.3% | 0.37 | 20.2% |
| Equity (SPY) | 12.2% | 17.1% | 0.53 | 25.0% |
| Gold (GLD) | 16.2% | 19.0% | 0.68 | 3.7% |
| Commodities (DBC) | 9.2% | 19.5% | 0.35 | 1.9% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 17.0% |
| Bitcoin (BTCUSD) | 4.9% | 51.6% | 0.28 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ORMP | |
|---|---|---|---|---|
| ORMP | -4.4% | 72.3% | 0.30 | - |
| Sector ETF (XLV) | 12.0% | 16.8% | 0.59 | 16.9% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 21.6% |
| Gold (GLD) | 11.4% | 16.5% | 0.56 | -0.0% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 5.6% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.21 | 14.1% |
| Bitcoin (BTCUSD) | 61.8% | 66.2% | 1.02 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/17/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/17/2025 | 0.4% | 10.7% | 30.0% |
| 11/10/2022 | 14.7% | 23.3% | 27.1% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 2 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 7.6% | 17.0% | 28.5% |
| Median Negative | |||
| Max Positive | 14.7% | 23.3% | 30.0% |
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/17/2025 | 0.4% | 10.7% | 30.0% |
| 11/10/2022 | 14.7% | 23.3% | 27.1% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 2 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 7.6% | 17.0% | 28.5% |
| Median Negative | |||
| Max Positive | 14.7% | 23.3% | 30.0% |
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/19/2026 | 10-Q |
| 12/31/2025 | 03/26/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/19/2026 | 10-Q |
| 12/31/2025 | 03/26/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-QT |
| 11/30/2021 | 01/11/2022 | 10-Q |
| 08/31/2021 | 11/24/2021 | 10-K |
| 05/31/2021 | 07/14/2021 | 10-Q |
| 02/28/2021 | 04/13/2021 | 10-Q |
| 11/30/2020 | 01/14/2021 | 10-Q |
| 08/31/2020 | 11/24/2020 | 10-K |
| 05/31/2020 | 07/07/2020 | 10-Q |
| 02/29/2020 | 04/06/2020 | 10-Q |
| 11/30/2019 | 01/09/2020 | 10-Q |
Insider Activity
Updated 10/2/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gabay, Avraham | Chief Financial Officer | Direct | Sell | 10022026 | 4.51 | 20,000 | 90,200 | 3,883,453 | Form |
| 2 | Hexter, Joshua | COO & CBO | Direct | Sell | 10022026 | 4.51 | 30,000 | 135,330 | 5,991,194 | Form |
| 3 | Hexter, Joshua | COO & CBO | Direct | Sell | 7022026 | 4.46 | 137,000 | 611,431 | 4,567,363 | Form |
| 4 | Gabay, Avraham | Chief Financial Officer | Direct | Sell | 7022026 | 4.51 | 73,360 | 330,744 | 3,028,743 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gabay, Avraham | Chief Financial Officer | Direct | Sell | 10022026 | 4.51 | 20,000 | 90,200 | 3,883,453 | Form |
| 2 | Hexter, Joshua | COO & CBO | Direct | Sell | 10022026 | 4.51 | 30,000 | 135,330 | 5,991,194 | Form |
| 3 | Hexter, Joshua | COO & CBO | Direct | Sell | 7022026 | 4.46 | 137,000 | 611,431 | 4,567,363 | Form |
| 4 | Gabay, Avraham | Chief Financial Officer | Direct | Sell | 7022026 | 4.51 | 73,360 | 330,744 | 3,028,743 | Form |
Investor Activity (13F)
Updated Nov 1, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.